Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma.

Cantwell, B M

Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma. [electronic resource] - Cancer treatment reports Nov 1986 - 1335-6 p. digital

Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial

0361-5960


Adult
Drug Evaluation
Folic Acid--adverse effects
Folic Acid Antagonists--adverse effects
Humans
Mesothelioma--drug therapy
Middle Aged
Quinazolines--adverse effects